Establishment and characteristics of two syngeneic human osteosarcoma cell lines from primary tumor and skip metastases.
OBJECTIVE
To characterize and compare the different biological behaviors of 2 novel human osteosarcoma cell lines, Zos and Zos-M, established respectively from the primary tumor and the skip metastasis of an osteosarcoma patient.


METHODS
In vitro studies included morphological observations, karyotype analysis, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cell proliferation assay, and cell sensitivity to chemotherapeutic drugs. Subcutaneous and intravenous inoculations into nude mice were carried out to study the tumorigenicity and the metastatic potential. RT-PCR was performed to assess the expression of the osteoblastic markers and some metastasis-related genes.


RESULTS
Both cell lines remained stable for more than 100 passages in vitro without interruption. The RT-PCR examination indicated that they retained the molecular characteristics of an osteoblastic lineage. The karyotype analysis displayed aneuploidy and various structural abnormalities. Both cell lines are tumorigenic; Zos-M differs from Zos by the former's ability to develop lung metastasis after intravenous injection. The comparison of the expression patterns of some metastasis-related genes revealed that the decreased expression of cadherin-11 in Zos-M may correlate with a high potential of metastases. Moreover, both cell lines are less sensitive to the current chemotherapy protocols.


CONCLUSIONS
The establishment of osteosarcoma cell lines, Zos and Zos-M, and related animal models provide a useful resource for studying the aggressive behavior of osteosarcoma and will be helpful for screening effective treatment strategies.
Zou
Chang-ye
CY
Department of Musculoskeletal Oncology, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China.
Wang
Jin
J
Shen
Jing-nan
JN
Huang
Gang
G
Jin
Song
S
Yin
Jun-qiang
JQ
Guo
Qian-chen
QC
Li
Hao-miao
HM
Luo
Lan
L
Zhang
Meng
M
Zhang
Long-Juan
LJ
D000293:Adolescent; D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D014408:Biomarkers, Tumor / Q000378:metabolism*; D045744:Cell Line, Tumor; D019070:Cell Lineage; D049109:Cell Proliferation / Q000187:drug effects; D003094:Collagen / Q000378:metabolism; D004338:Drug Combinations; D005109:Extracellular Matrix / Q000378:metabolism; D005562:Formazans / Q000378:metabolism; D006801:Humans; D020128:Inhibitory Concentration 50; D007621:Karyotyping; D007797:Laminin / Q000378:metabolism; D008297:Male; D008727:Methotrexate / Q000494:pharmacology; D051379:Mice; D008819:Mice, Nude; D009362:Neoplasm Metastasis / Q000473:pathology; D012516:Osteosarcoma / Q000235:genetics / Q000473:pathology* / Q000556:secondary* / Q000648:ultrastructure; D011509:Proteoglycans / Q000378:metabolism; D013778:Tetrazolium Salts / Q000378:metabolism; D023041:Xenograft Model Antitumor Assays
D000964:Antimetabolites, Antineoplastic; D014408:Biomarkers, Tumor; D004338:Drug Combinations; D005562:Formazans; D007797:Laminin; D011509:Proteoglycans; D013778:Tetrazolium Salts; C059485:matrigel; C079782:MTT formazan; D003094:Collagen; D008727:Methotrexate